View Clinical trials for Fezolinetant Get Fezolinetant Patent Info for Free

Fezolinetant is the first NK3 antagonist which has been optimized for use in women’s health, and is being developed for sex-hormone related disorders such as endometriosis, polycystic ovarian syndrome and uterine fibroids. ESN-364 is an oral available small molecule which, due to its unique mechanism of action, allows modulation of the hypothalamic-pituitary gonadal axis with a selective action on hormones relevant to disease. As such, the agent is expected to have greater tolerability than competing products which target GnRH.

Inn NameFezolinetant
Lab CodesESN-364
Chemical Name(4-fluorophenyl)[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]methanone
Chemical StructureFezolinetant.png
Molecular FormulaC16H15FN6OS
Cas Registry Number1629229-37-3
New Molecular EntityYes
Mechanism Of ActionNeurokinin-3 (NK-3) receptor antagonist
Who Atc CodesG02 (Other Gynecologicals), G04C (Drugs Used In Benign Prostatic Hypertrophy)
Ephmra CodesG2 (Other Gynaecologicals), G4C (BPH (Benign Prostatic Hypertrophy) Products)

Free counters!